BR112023017989A2 - Composição de primer-sonda, kit, e método de detecção - Google Patents

Composição de primer-sonda, kit, e método de detecção

Info

Publication number
BR112023017989A2
BR112023017989A2 BR112023017989A BR112023017989A BR112023017989A2 BR 112023017989 A2 BR112023017989 A2 BR 112023017989A2 BR 112023017989 A BR112023017989 A BR 112023017989A BR 112023017989 A BR112023017989 A BR 112023017989A BR 112023017989 A2 BR112023017989 A2 BR 112023017989A2
Authority
BR
Brazil
Prior art keywords
primer
kit
probe composition
detection method
group
Prior art date
Application number
BR112023017989A
Other languages
English (en)
Inventor
Hao Jing
Liu Nan
Wang Ning
Xie Yanbin
Original Assignee
Ascentawits Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascentawits Pharmaceuticals Ltd filed Critical Ascentawits Pharmaceuticals Ltd
Publication of BR112023017989A2 publication Critical patent/BR112023017989A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

composição de primer-sonda, kit, e método de detecção. a presente invenção refere-se a uma composição de primer-sonda, um kit e um método de detecção. a composição de primer-sonda é selecionada a partir de um grupo do grupo (i) ao grupo (ix), e o kit compreende a composição de primer-sonda. de acordo com a presente invenção, a detecção do conte-údo de rna de akric3 em uma amostra ex vivo de um paciente pode ser alcançada.
BR112023017989A 2021-03-05 2021-03-05 Composição de primer-sonda, kit, e método de detecção BR112023017989A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/079299 WO2022183483A1 (zh) 2021-03-05 2021-03-05 一种引物探针组合物、试剂盒和检测方法

Publications (1)

Publication Number Publication Date
BR112023017989A2 true BR112023017989A2 (pt) 2023-12-12

Family

ID=83154869

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017989A BR112023017989A2 (pt) 2021-03-05 2021-03-05 Composição de primer-sonda, kit, e método de detecção

Country Status (11)

Country Link
US (1) US20240175092A1 (pt)
EP (1) EP4303322A1 (pt)
JP (1) JP2024508546A (pt)
KR (1) KR20230154252A (pt)
CN (1) CN116324417A (pt)
AU (1) AU2021431102A1 (pt)
BR (1) BR112023017989A2 (pt)
CA (1) CA3211243A1 (pt)
IL (1) IL305194A (pt)
TW (1) TW202300657A (pt)
WO (1) WO2022183483A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102034618B1 (ko) 2015-03-10 2019-10-21 아센타위츠 파마슈티컬즈 리미티드 Dna 알킬화제
CA2981494C (en) 2015-04-02 2023-09-05 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
AU2016357728B2 (en) 2015-11-16 2020-08-27 Obi Pharma, Inc. (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
JP7084034B2 (ja) 2016-12-28 2022-06-14 国立大学法人神戸大学 神経芽腫の微小残存病変を評価するために用いられる試薬、およびそれを用いた生体試料の分析方法
TW201919644A (zh) 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
WO2019190331A1 (en) 2018-03-29 2019-10-03 Achilles Medical Limited Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders
CN111876478A (zh) * 2020-04-28 2020-11-03 中国科学院微生物研究所 肺结节诊断标志物及应用

Also Published As

Publication number Publication date
EP4303322A1 (en) 2024-01-10
AU2021431102A1 (en) 2023-09-21
TW202300657A (zh) 2023-01-01
JP2024508546A (ja) 2024-02-27
CA3211243A1 (en) 2022-09-09
IL305194A (en) 2023-10-01
WO2022183483A1 (zh) 2022-09-09
CN116324417A (zh) 2023-06-23
KR20230154252A (ko) 2023-11-07
US20240175092A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
Webb et al. Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery
Kitamoto et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease
Yan et al. Endogenous hydrogen sulfide formation mediates the liver damage in endotoxemic rats
Materazzi et al. Vasodilator activity of hydrogen sulfide (H2S) in human mesenteric arteries
BRPI0910821A8 (pt) Método para modificar uma proteína, alimento, preparação de enzima para modificar uma proteína, e, método para estabelecer uma relação ótima de proteína glutaminase para transglutaminase
BR112014013544A8 (pt) materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata
BR112014000843A8 (pt) Uso de picosulfato para preparação de composição intestinal para o cálculo da duração de colonoscopia, composição intestinal e kit
EA201290158A1 (ru) Композиция и способ лечения диабета
MX2012005126A (es) Composiciones y metodos para tratar condiciones dermatologicas.
BR112012019215A2 (pt) identificação, avaliação e terapia de cãnceres com resistência congênita ou adquirida a inibidores de alk.
Takeuchi et al. Alleviation of fatty liver in a rat model by enhancing N1-methylnicotinamide bioavailability through aldehyde oxidase inhibition
BR112023017989A2 (pt) Composição de primer-sonda, kit, e método de detecção
Liu et al. Role and mechanism of homocysteine in affecting hepatic protein-tyrosine phosphatase 1B
BR112021021744A8 (pt) Métodos para tratar hemoglobinopatia e para determinar se um indivíduo sofrendo de hemoglobinopatia é adequado ou inadequado para tratar com uma segunda população das hspcs positivas em cd34 modificadas
WO2007101191A3 (en) Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors
BR112022004757A2 (pt) Composições de hidrolizado de proteína microbiana e métodos para fazer as mesmas
CN108060238A (zh) 原奶或发酵乳中牛和马源性检测的引物和探针及试剂盒
BRPI0509753A (pt) composição farmacêutica e método de tratamento de doença cardiovascular
BR112023010521A2 (pt) Biomarcadores de agonista de trem2 e métodos de uso dos mesmos
Ei et al. Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar
EA201200529A1 (ru) Флуорофор в форме частиц и способ его получения
BRPI0519519A2 (pt) procedimento para detectar o aumento de isoformas de apolipoproteÍna "ai" oxidadas e kit para determinar o aumento da isoforma
La Fuente et al. Erectile dysfunction is associated with defective L-cysteine/hydrogen sulfide pathway in human corpus cavernosum and penile arteries
RU2019116069A (ru) Новые биомаркеры старения кожи человека
Sun et al. Metabolic profiling associated with autophagy of human placenta-derived mesenchymal stem cells by chemical isotope labeling LC− MS